Posted by Michael Wonder on 10 Apr 2018
ICER publishes guidance on improving the development and use of real world evidence for drug coverage and formulary decisions
10 April 2018 - The ICER, in collaboration with the Office of Health Economics, has released two new white papers to provide guidance to payers and manufacturers on the development and use of real world evidence for drug coverage and formulary decisions.
The papers were generated as part of the annual ICER Policy Summit, where life science and payer organisations meet to develop collaborative approaches to addressing key policy issues related to the generation and application of evidence to improve value in the US health care system.
The first paper, entitled Real World Evidence for Coverage Decisions: Opportunities and Challenges, was developed as the background paper for the December 2017 Policy Summit of ICER's membership program, where leaders from 22 payer and life science organisations convened to share their perspectives on challenges and opportunities for this type of evidence. This paper highlights the challenges associated with wider use of real world evidence, including increased potential for bias, the risks of incomplete data, and the lack of universally accepted methodological standards.
